The TFOS DEWS III Leadership group recently met in London, UK, to discuss in detail all questions and any issues related to this TFOS initiative. The TFOS DEWS III report is almost complete, and will be submitted soon to a leading ophthalmic journal for publication.
The mission of TFOS DEWS III is to achieve a global consensus concerning multiple aspects of dry eye disease. More specifically, TFOS DEWS III is updating the recommendations of TFOS DEWS II concerning the subclassification, diagnostic methodology, and management and therapy of this disease. TFOS DEWS III is also creating a Digest, that will highlight new advances in other TFOS DEWS II topics, including epidemiology; sex, gender, and hormones; pathophysiology; tear film; pain and sensation; iatrogenic dry eye; and clinical trials. TFOS DEWS III involves the efforts of clinical and basic science research experts from around the world, who are utilizing an evidence-based approach and a process of open communication, dialogue and transparency to increase our understanding of dry eye disease.
As noted by an internationally renowned ophthalmologist, “The publication of the [original TFOS] DEWS Report…was a landmark event in the history of our understanding and treatment of dry eye disease.” The global impact of the TFOS DEWS II report was even more amazing. This TFOS DEWS III report will create another major landmark in our understanding of this extremely prevalent ocular disease.
